United States Biotechnology & Medical Research

Syndax Pharmaceuticals Inc (SNDX)

Track

Over the past 90 days, Syndax Pharmaceuticals Inc. insiders have engaged in 13 transactions, all of which were sales. Key executives, including the CEO and CMO, executed planned sales totaling approximately $5.99 million. These transactions occurred following the company's April 2026 earnings report, where the firm reported an earnings beat of 18.64%.
Ticker: SNDX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Syndax Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 8 Jul 2026
Value US$3,391,627.17 | Price 287.00 | Shares 35,611 (+24.3%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-09 2026-07-08 PlS Planned sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
35,611 +24.3%
287.00
US$3,391,627 		35,611 +24.3% 287.00 US$3,391,627
2026-07-08 2026-07-08 PrS Proposed sale
2.7
MICHAEL METZGER

Director; Officer

Executive Director
56,312
363.77
US$4,869,289 		56,312 363.77 US$4,869,289
2026-06-12 2026-06-12 PlS Planned sale
3.3
Botwood Nicholas A.J.

Head of R&D, CMO

Officer
42,496 -20.7%
84.99
US$4,046,635 		42,496 -20.7% 84.99 US$4,046,635
2026-06-12 2026-06-12 PlS Planned sale
3.3
Botwood Nicholas A.J.

Head of R&D, CMO

Officer
31,235 -33.9%
18.14
US$566,603 		31,235 -33.9% 18.14 US$566,603
2026-06-12 2026-06-12 PrS Proposed sale
3.3
Botwood Nicholas A.J.

Officer

Officer
31,235
18.14
US$566,693 		31,235 18.14 US$566,693
2026-06-12 2026-06-11 PlS Planned sale
3.3
Botwood Nicholas A.J.

Head of R&D, CMO

Officer
34,280 -36.0%
18.00
US$617,040 		34,280 -36.0% 18.00 US$617,040
2026-06-12 2026-06-11 PlS Planned sale
3.3
Botwood Nicholas A.J.

Head of R&D, CMO

Officer
34,280 -36.0%
18.00
US$617,040 		34,280 -36.0% 18.00 US$617,040
2026-06-11 2026-06-11 PrS Proposed sale
3.3
Botwood Nicholas A.J.

Officer

Officer
34,280
17.78
US$609,435 		34,280 17.78 US$609,435
2026-06-11 2026-06-11 PrS Proposed sale
3.3
Botwood Nicholas A.J.

Officer

Officer
34,280
17.78
US$609,435 		34,280 17.78 US$609,435
2026-06-02 2026-06-01 S Sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
6,847 -1.4%
18.99
US$130,025 		6,847 -1.4% 18.99 US$130,025
2026-06-02 2026-06-01 S Sale
2.0
Goldan Keith A.

Chief Financial Officer

Officer
1,177 -0.8%
18.99
US$22,351 		1,177 -0.8% 18.99 US$22,351
2026-06-01 2026-06-01 PrS Proposed sale
2.0
Goldan Keith A.

Officer

Officer
1,177
18.99
US$22,352 		1,177 18.99 US$22,352
2026-06-01 2026-06-01 PrS Proposed sale
2.7
Metzger Michael A

Officer; Director

Executive Director
6,847
18.99
US$130,028 		6,847 18.99 US$130,028
2026-02-10 2026-02-09 S Sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
17,159 -3.4%
21.03
US$360,819 		17,159 -3.4% 21.03 US$360,819
2026-02-10 2026-02-09 S Sale
2.0
Goldan Keith A.

Chief Financial Officer

Officer
3,410 -2.4%
21.03
US$71,705 		3,410 -2.4% 21.03 US$71,705
2026-02-09 2026-02-09 PrS Proposed sale
2.7
Metzger Michael A

Officer; Director

Executive Director
17,159
21.03
US$360,826 		17,159 21.03 US$360,826
2026-02-09 2026-02-09 PrS Proposed sale
2.0
Goldan Keith A.

Officer

Officer
3,410
21.03
US$71,707 		3,410 21.03 US$71,707
2026-02-06 2026-02-06 S Sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
7,412 -1.4%
20.62
US$152,835 		7,412 -1.4% 20.62 US$152,835
2026-02-06 2026-02-06 S Sale
2.0
Goldan Keith A.

Chief Financial Officer

Officer
2,082 -1.4%
20.62
US$42,931 		2,082 -1.4% 20.62 US$42,931
2026-02-06 2026-02-06 PrS Proposed sale
2.7
Metzger Michael A

Officer; Director

Executive Director
7,412
20.62
US$152,836 		7,412 20.62 US$152,836
2026-02-06 2026-02-06 PrS Proposed sale
2.0
Goldan Keith A.

Officer

Officer
2,082
20.62
US$42,931 		2,082 20.62 US$42,931
2025-09-08 2025-09-08 PrS Proposed sale
2.7
MICHAEL METZGER

Director; Officer

Executive Director
157,307
17.04
US$2,680,511 		157,307 17.04 US$2,680,511
2025-09-08 2025-09-08 PlS Planned sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
157,307 -34.5%
16.41
US$2,582,021 		157,307 -34.5% 16.41 US$2,582,021
2025-08-18 2025-08-18 PrS Proposed sale
3.0
DENNIS G PODLESAK

Director

Non-Executive Director
14,400
15.74
US$226,656 		14,400 15.74 US$226,656
2025-08-18 2025-08-18 PlS Planned sale
3.0
Podlesak Dennis
Non-Executive Director
19,200 -9.1%
15.84
US$304,170 		19,200 -9.1% 15.84 US$304,170
2025-08-18 2025-08-15 PlS Planned sale
3.0
Podlesak Dennis
Non-Executive Director
19,200 -9.1%
15.54
US$298,408 		19,200 -9.1% 15.54 US$298,408
2025-08-18 2025-08-14 PlS Planned sale
3.0
Podlesak Dennis
Non-Executive Director
19,200 -9.1%
14.19
US$272,521 		19,200 -9.1% 14.19 US$272,521
2025-08-14 2025-08-14 PrS Proposed sale
3.0
DENNIS G PODLESAK

Director

Non-Executive Director
43,200
13.45
US$581,040 		43,200 13.45 US$581,040
2025-07-18 2025-07-16 S Sale
2.0
Goldan Keith A.

Chief Financial Officer

Officer
1,296 -1.4%
9.29
US$12,033 		1,296 -1.4% 9.29 US$12,033
2025-07-18 2025-07-16 S Sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
7,534 -2.5%
9.29
US$69,953 		7,534 -2.5% 9.29 US$69,953
2025-07-16 2025-07-16 PrS Proposed sale
2.0
Goldan Keith A.

Officer

Officer
1,296
9.29
US$12,034 		1,296 9.29 US$12,034
2025-07-16 2025-07-16 PrS Proposed sale
2.7
Metzger Michael A

Officer; Director

Executive Director
7,534
9.29
US$69,955 		7,534 9.29 US$69,955
2025-07-10 2025-07-10 PrS Proposed sale
3.2
Gallagher Neil

Officer

Officer
9,679
9.26
US$89,667 		9,679 9.26 US$89,667
2025-05-19 2025-05-19 B Purchase
3.2
Katkin Keith
Non-Executive Director
10,000 +11.1%
9.11
US$91,120 		10,000 +11.1% 9.11 US$91,120
2025-05-19 2025-05-19 B Purchase
3.2
Huber Martin H. Jr.
Non-Executive Director
5,000 +6.8%
8.99
US$44,950 		5,000 +6.8% 8.99 US$44,950
2025-05-19 2025-05-16 B Purchase
3.3
Botwood Nicholas A.J.

Head of R&D, CMO

Officer
11,765 +50.3%
9.00
US$105,826 		11,765 +50.3% 9.00 US$105,826
2025-03-06 2025-03-04 PlS Planned sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
7,814 -2.5%
15.05
US$117,564 		7,814 -2.5% 15.05 US$117,564
2025-03-04 2025-03-04 PrS Proposed sale
2.7
MICHAEL METZGER

Officer

Officer
13,888
15.48
US$214,986 		13,888 15.48 US$214,986
2025-02-12 2025-02-10 S Sale
3.2
Gallagher Neil

President, Head of R&D

Officer
4,618 -5.1%
15.50
US$71,597 		4,618 -5.1% 15.50 US$71,597
2025-02-12 2025-02-10 S Sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
13,288 -4.2%
15.50
US$206,017 		13,288 -4.2% 15.50 US$206,017
2025-02-12 2025-02-10 S Sale
2.0
Goldan Keith A.

Chief Financial Officer

Officer
3,777 -4.0%
15.50
US$58,559 		3,777 -4.0% 15.50 US$58,559
2025-02-10 2025-02-10 PrS Proposed sale
2.0
Goldan Keith A.

Officer

Officer
3,777
15.50
US$58,559 		3,777 15.50 US$58,559
2025-02-10 2025-02-10 PrS Proposed sale
2.7
Metzger Michael A

Officer; Director

Executive Director
13,288
15.50
US$206,017 		13,288 15.50 US$206,017
2025-02-10 2025-02-10 PrS Proposed sale
3.2
Gallagher Neil

Officer

Officer
4,618
15.50
US$71,597 		4,618 15.50 US$71,597
2024-06-17 2024-06-14 B Purchase
2.0
Goldan Keith A.

Chief Financial Officer

Officer
1,250 +2.4%
20.03
US$25,037 		1,250 +2.4% 20.03 US$25,037
2023-08-10 2023-08-09 S Sale
3.3
Morrison Briggs
Non-Executive Director
52,855 -74.8%
18.27
US$965,402 		52,855 -74.8% 18.27 US$965,402
2023-08-09 2023-08-09 PrS Proposed sale
3.3
BRIGGS MORRISON

Director

Non-Executive Director
52,855
18.25
US$964,604 		52,855 18.25 US$964,604
2023-08-03 2023-08-02 S Sale
3.1
Meury William
Non-Executive Director
24,000 -33.3%
20.45
US$490,913 		24,000 -33.3% 20.45 US$490,913
2023-08-03 2023-08-02 S Sale
3.1
Meury William
Non-Executive Director
24,000 -33.3%
20.46
US$490,951 		24,000 -33.3% 20.46 US$490,951
2023-08-03 2023-08-02 S Sale
3.1
Meury William
Non-Executive Director
35,000 -42.2%
20.46
US$715,946 		35,000 -42.2% 20.46 US$715,946
2023-08-02 2023-08-02 PrS Proposed sale
3.1
Meury William

Director

Non-Executive Director
83,000
20.46
US$1,697,811 		83,000 20.46 US$1,697,811
2023-07-11 2023-07-10 S Sale
3.3
Morrison Briggs
Non-Executive Director
52,855 -74.8%
20.40
US$1,078,068 		52,855 -74.8% 20.40 US$1,078,068
2023-07-10 2023-07-10 PrS Proposed sale
3.3
BRIGGS MORRISON

Director

Non-Executive Director
52,855
20.30
US$1,072,956 		52,855 20.30 US$1,072,956
2023-06-14 2023-06-13 S Sale
2.0
Goldan Keith A.

Chief Financial Officer

Officer
577 -18.0%
22.31
US$12,873 		577 -18.0% 22.31 US$12,873
2023-06-09 2023-06-09 PrS Proposed sale
3.3
BRIGGS W MORRISON

Director

Non-Executive Director
52,855
21.32
US$1,126,869 		52,855 21.32 US$1,126,869
2023-06-09 2023-06-09 S Sale
3.3
Morrison Briggs
Non-Executive Director
28,273 -61.3%
21.18
US$598,797 		28,273 -61.3% 21.18 US$598,797
2023-06-09 2023-06-09 S Sale
3.3
Morrison Briggs
Non-Executive Director
24,582 -34.8%
21.18
US$520,625 		24,582 -34.8% 21.18 US$520,625
2023-05-10 2023-05-09 S Sale
3.3
Morrison Briggs
Non-Executive Director
52,855 -74.8%
21.41
US$1,131,478 		52,855 -74.8% 21.41 US$1,131,478
2023-05-09 2023-05-09 PrS Proposed sale
3.3
BRIGGS W MORRISON &ANGELA HOOVER MORRISON JT TEN

Officer

Officer
52,855
20.29
US$1,072,428 		52,855 20.29 US$1,072,428
2023-04-12 2023-04-10 S Sale
3.3
Morrison Briggs
Non-Executive Director
52,855 -74.8%
19.53
US$1,032,237 		52,855 -74.8% 19.53 US$1,032,237
2023-03-14 2023-03-13 PlS Planned sale
3.3
Morrison Briggs

President, Head of R&D

Executive Director
52,854 -74.8%
22.53
US$1,190,674 		52,854 -74.8% 22.53 US$1,190,674
2023-02-17 2023-02-15 PlS Planned sale
2.1
Ordentlich Peter

Chief Scientific Officer

Officer
17,428 -100.0%
25.84
US$450,404 		17,428 -100.0% 25.84 US$450,404
2023-02-17 2023-02-15 PlS Planned sale
2.1
Ordentlich Peter

Chief Scientific Officer

Officer
7,572 -100.0%
25.84
US$195,688 		7,572 -100.0% 25.84 US$195,688
2023-02-08 2023-02-06 PlS Planned sale
3.3
Morrison Briggs

President, Head of R&D

Executive Director
52,854 -74.8%
26.83
US$1,417,909 		52,854 -74.8% 26.83 US$1,417,909
2023-02-08 2023-02-06 PlS Planned sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
5,959 -25.2%
27.64
US$164,697 		5,959 -25.2% 27.64 US$164,697
2023-02-03 2023-02-01 S Sale
2.1
Ordentlich Peter

Chief Scientific Officer

Officer
69 -100.0%
28.43
US$1,962 		69 -100.0% 28.43 US$1,962
2023-01-13 2023-01-13 PlS Planned sale
1.5
Legault Pierre
Non-Executive Director
5,000 -13.5%
27.00
US$135,000 		5,000 -13.5% 27.00 US$135,000
2023-01-13 2023-01-13 PlS Planned sale
1.5
Legault Pierre
Non-Executive Director
10,000 -23.8%
27.00
US$270,000 		10,000 -23.8% 27.00 US$270,000
2023-01-13 2023-01-12 PlS Planned sale
1.5
Legault Pierre
Non-Executive Director
24,000 -42.9%
26.74
US$641,782 		24,000 -42.9% 26.74 US$641,782
2022-12-02 2022-12-02 PlS Planned sale
2.1
Ordentlich Peter

Chief Scientific Officer

Officer
17,200 -98.5%
25.05
US$430,936 		17,200 -98.5% 25.05 US$430,936
2022-12-02 2022-12-01 PlS Planned sale
2.1
Ordentlich Peter

Chief Scientific Officer

Officer
4,028 -93.8%
25.01
US$100,746 		4,028 -93.8% 25.01 US$100,746
2022-12-02 2022-12-01 PlS Planned sale
2.1
Ordentlich Peter

Chief Scientific Officer

Officer
3,772 -93.4%
25.01
US$94,343 		3,772 -93.4% 25.01 US$94,343
2022-10-07 2022-10-06 PlS Planned sale
3.2
Katkin Keith
Non-Executive Director
9,117 -22.2%
25.90
US$236,139 		9,117 -22.2% 25.90 US$236,139
2022-10-07 2022-10-06 PlS Planned sale
3.2
Katkin Keith
Non-Executive Director
20,782 -39.4%
25.90
US$538,273 		20,782 -39.4% 25.90 US$538,273
2022-10-07 2022-10-06 PlS Planned sale
2.7
Metzger Michael A

Chief Executive Officer

Executive Director
16,231 -47.9%
25.29
US$410,508 		16,231 -47.9% 25.29 US$410,508
Explore more

More insider trading research around Syndax Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America